Business & Finance

Sepracor reports Q3 2006 consolidated revenues of $289.3 million

Published in Biotech Business Week, November 27th, 2006

Sepracor Inc. (SEPR) reported in its financial results for the third quarter ended September 30, 2006, that its consolidated revenues were $289.3 million, of which revenues from pharmaceutical product sales were $280.1 million, $138.5 million for sales of Xopenex brand levalbuterol products and $141.6 million for sales of Lunesta brand eszopiclone.

Revenues for the third quarter of 2006 include $8.3 million, $4.2 million related to Xopenex brand levalbuterol product sales and $4.1 million related to Lunesta brand eszopiclone sales, resulting from the reversal of reserves relating to rebates under the U.S. Department of Veterans Affairs (VA), Tricare Pharmacy Benefits...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2006-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry